Sulis, Maria L
Mayo Clinic
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.
Citations 1
MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231
Hayashi, Robert J. , Hermiston, Michelle L. , Wood, Brent L. , Teachey, David T. , Devidas, Meenakshi , Chen, Zhiguo , Annett, Robert D. , Asselin, Barbara L. , August, Keith J. , Cho, Steve , Galardy, Paul J. , Harker‐Murray, Paul , Jaju, Alok , Lam, Allison, Miles, Rodney R., Okada, Maki , Patel, Samir , Schechter, Tal , Shimano, Kristin A. , Singh, Neelam, Steele, Amii C., Sulis, Maria Luisa , Vargas, Sarah , Winter, Stuart S. , Wood, Charlotte, Loh, Mignon L. , Raetz, Elizabeth A. , Bollard, Catherine M. , Allen, Carl E. , August, Keith , Freedman, Jason Lawrence , Galardy, Paul J , Harker-Murray, Paul , Horton, Terzah M. , Jaju, Alok I , Messinger, Yoav H , Okada, Maki , Schafer, Eric S , Shimano, Kristin A , Sulis, Maria L , Winter, Stuart S , Zweidler-McKay, Patrick A , Loh, Mignon L , Hunger, Stephen P , Raetz, Elizabeth A , Bollard, Catherine M , Allen, Carl E , Wood, Brent L , Devidas, Meenakshi , Dunsmore, Kimberly P , Messinger, Yoav H. , Schafer, Eric S. , Hunger, Stephen P.
Blood | March 8, 2024 | Volume: 143 | Issue: 20 | Pages: 2053-2058
Abstract Defining prognostic variables in T-lymphoblastic lymphoma (T-LL) remains a challenge. AALL1231 was a Children’s Oncology Group phase 3 clinical trial for newly diagnosed patients with T acute lymphoblastic leukemia or T-LL, randomizing children and young adults to a modified augmented Berlin-Frankfurt-Münster backbone to receive standard therapy (arm A) or with addition of bortezomib (arm B). Optional bone marrow samples to assess minimal residual disease (MRD) at the end of induction (EOI) were collected in T-LL analyzed to assess the correlation of MRD at the EOI to event-free survival (EFS). Eighty-six (41%) of the 209 patients with T-LL accrued to this trial submitted samples for MRD assessment. Patients with MRD <0.1% (n = 75) at EOI had a superior 4-year EFS vs those with MRD ≥0.1% (n = 11) (89.0% ± 4.4% vs 63.6% ± 17.2%; P = .025). Overall survival did not significantly differ between the 2 groups. Cox regression for EFS using arm A as a reference demonstrated that MRD EOI ≥0.1% was associated with a greater risk of inferior outcome (hazard ratio, 3.73; 95% confidence interval, 1.12-12.40; P = .032), which was independent of treatment arm assignment. Consideration to incorporate MRD at EOI into future trials will help establish its value in defining risk groups. CT# NCT02112916.